Format

Send to

Choose Destination
Anticancer Res. 2019 Aug;39(8):4581-4588. doi: 10.21873/anticanres.13637.

Clinical Features of Recurrence in Patients Without Residual Tumour in Endometrial Cancer.

Author information

1
Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
2
Department of Obstetrics and Gynecology, Japanese Red Cross Yamaguchi Hospital, Yamaguchi, Japan.
3
Department of Obstetrics and Gynecology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
4
Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan smiya@cis.fukuoka-u.ac.jp.

Abstract

BACKGROUND/AIM:

Initial treatment of endometrial cancer with surgery and platinum and taxane-based chemotherapy is often successful, but it remains unclear as to whether certain types of the disease relapse. The aim of this study was to identify the clinical features of recurrence in patients without residual tumour in endometrial cancer.

PATIENTS AND METHODS:

Clinical features, histological type, and time to recurrence were analyzed in 640 endometrial cancer patients without residual tumours.

RESULTS:

Of 640 patients, 517 were type I and 123 were type II. For type I, early recurrent (ER) disease and late recurrent (LR) disease were noted in 80 and 8 patients, respectively, and 97.5% of ER occurred within 2 years. After recurrence, 76.2% of ER and 50% of LR patients died. In type II, ER and LR were noted in 41 and 1 patients, respectively, and 97.6% of ER occurred within 2 years, of which 75.6% died after recurrence. One LR case died of disease.

CONCLUSION:

Most patients recurred within 2 years irrespective of clinical stage or type.

KEYWORDS:

Endometrial cancer; Type I; Type II; late recurrence

PMID:
31366563
DOI:
10.21873/anticanres.13637
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center